The GPHN Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population generated from HT29 human colorectal adenocarcinoma cells, where GPHN gene disruption eliminates functional gephyrin protein. This pooled format circumvents clonal selection bias and captures the genetic heterogeneity intrinsic to cancer cell populations, offering a more representative model for functional studies. The knockout product is supplied as a mixed population, enabling researchers to investigate gephyrin-dependent processes without concerns over clone-specific anomalies.
HT29 is a well-established epithelial cell line derived from a female colorectal adenocarcinoma, harboring mutations in APC, TP53, and BRAF (V600E), and displaying constitutive mTOR pathway activity. These cells are widely used to study colon cancer biology, including proliferation, migration, invasion, and autophagy, as well as responses to targeted therapies such as mTOR inhibitors. The HT29 background provides a highly relevant context for exploring gephyrin??s non-neuronal functions in a clinically significant cancer model.
Gephyrin is a multifunctional scaffold that clusters inhibitory neurotransmitter receptors via interactions with GABA(A) receptor subunits, glycine receptor subunits, collybistin, and GABARAP. In non-neuronal cells, gephyrin interfaces with the mTORC1/S6K signaling axis and ULK1-driven autophagy, acting downstream of PKA and PKC and physically associating with mTOR. This places gephyrin at a convergence point between synaptic organization and nutrient-responsive pathways, making GPHN knockout cells valuable for dissecting how these interactions govern cell growth and metabolism.
In the HT29 colorectal cancer context, GPHN disruption compromises mTORC1/S6K signaling and attenuates autophagy flux, as indicated by reduced S6K phosphorylation and altered LC3 processing. These defects are predicted to impair cell proliferation and migration, given the established roles of mTOR and autophagy in colorectal cancer progression. The polyclonal knockout model thus enables detailed examination of how gephyrin loss affects tumorigenic properties and may uncover new non-synaptic interactors driving these phenotypes.
Applications include western blotting for phospho-S6K to monitor mTORC1 activity, LC3-based autophagy flux assays, wound healing and transwell migration/invasion studies, and drug sensitivity testing with mTOR inhibitors. Co-immunoprecipitation and immunofluorescence can identify gephyrin binding partners and subcellular localization. This model is suited for mechanistic studies into colorectal cancer signaling, target validation, and the discovery of non-neuronal gephyrin functions. For additional information or tailored experimental support, please contact Ascent Research.
